Cerus Corporation engages in the development and commercialization of novel and proprietary products and technologies in the fields of blood safety and immunotherapy in the United States, Europe, and Japan. It offers INTERCEPT Blood System for platelets, plasma, and red blood cells. INTERCEPT Blood System is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites, and other pathogens, as well as white blood cells. The company is also developing cancer immunotherapies based on its Listeria vaccine platform combined with disease antigens. Its products include CRS-100, which is in phase I clinical trial for the treatment of cancers that have...